Patents by Inventor Xiaoguang Lei
Xiaoguang Lei has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240018129Abstract: Disclosed herein are compounds of formula (I) that are PU.1 inhibitors. Also provided herein are methods or preparing these compounds.Type: ApplicationFiled: November 18, 2021Publication date: January 18, 2024Applicant: S-Infinity PharmaceuticalsInventors: Xiaoguang LEI, Hong WU, Xin WANG, Ningning YAO, Fusheng GUO
-
Patent number: 11293015Abstract: The present invention provides a Diels-Alderase and use thereof, and belongs to the field of gene engineering technology. The Diels-Alderase is MaDA, and its amino acid sequence and gene sequence are represented by SEQ ID Nos. 1 and 2, respectively. The present invention also provides MaDA-1 and MaDA-2, both of which are homologous proteins of MaDA, and their amino acid sequences are represented by SEQ ID Nos. 10 and 12, respectively. The present invention has discovered that MaDA and its homologous proteins from Morus alba can stereospecifically synthesize natural products of endo configuration, and prepare D-A type natural products and their analogs in vitro using chalcones and dehydroprenyl-containing compounds as substrates, which helps to develop and utilize the medicinal value of such natural products, and also provides a possibility to synthesize other six-membered ring-containing important chemical precursors or natural products.Type: GrantFiled: November 18, 2020Date of Patent: April 5, 2022Assignees: Peking University, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical CollegeInventors: Xiaoguang Lei, Jungui Dai, Lei Gao, Cong Su
-
Publication number: 20210147820Abstract: The present invention provides a Diels-Alderase and use thereof, and belongs to the field of gene engineering technology. The Diels-Alderase is MaDA, and its amino acid sequence and gene sequence are represented by SEQ ID Nos. 1 and 2, respectively. The present invention also provides MaDA-1 and MaDA-2, both of which are homologous proteins of MaDA, and their amino acid sequences are represented by SEQ ID Nos. 10 and 12, respectively. The present invention has discovered that MaDA and its homologous proteins from Morus alba can stereospecifically synthesize natural products of endo configuration, and prepare D-A type natural products and their analogs in vitro using chalcones and dehydroprenyl-containing compounds as substrates, which helps to develop and utilize the medicinal value of such natural products, and also provides a possibility to synthesize other six-membered ring-containing important chemical precursors or natural products.Type: ApplicationFiled: November 18, 2020Publication date: May 20, 2021Inventors: Xiaoguang Lei, Jungui DAI, Lei Gao, Cong Su
-
Patent number: 10682319Abstract: The invention provides amides that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.Type: GrantFiled: May 22, 2018Date of Patent: June 16, 2020Assignee: National Institute of Biological Sciences, BeijingInventors: Zhiyuan Zhang, Xiaodong Wang, Xiaoguang Lei, Yaning Su, Sudan He, Hanying Ruan, Liming Sun
-
Publication number: 20180263934Abstract: The invention provides amides that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.Type: ApplicationFiled: May 22, 2018Publication date: September 20, 2018Applicant: National Institute of Biological Sciences, BeijingInventors: Zhiyuan Zhang, Xiaodong Wang, Xiaoguang Lei, Yaning Su, Sudan He, Hanying Ruan, Liming Sun
-
Patent number: 9974762Abstract: The invention provides amides that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.Type: GrantFiled: June 26, 2017Date of Patent: May 22, 2018Assignee: National Institute of Biological Sciences, BeijingInventors: Zhiyuan Zhang, Xiaodong Wang, Xiaoguang Lei, Yaning Su, Sudan He, Hanying Ruan, Liming Sun
-
Publication number: 20170290790Abstract: The invention provides amides that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.Type: ApplicationFiled: June 26, 2017Publication date: October 12, 2017Applicant: National Institute of Biological Sciences, BeijingInventors: Zhiyuan Zhang, Xiaodong Wang, Xiaoguang Lei, Yaning Su, Sudan He, Hanying Ruan, Liming Sun
-
Patent number: 9670226Abstract: The invention provides novel compounds and compositions for inhibiting IKK?/?, including treating disorders associated with IKK?/? activity, including cancer, autoimmune and inflammatory disorders, with a compound of structure:Type: GrantFiled: October 24, 2016Date of Patent: June 6, 2017Assignee: National Institute of Biological Sciences, BeijingInventors: Xiaoguang Lei, Sudan He, Chao Li, Ting Dong
-
Publication number: 20170044180Abstract: The invention provides novel compounds and compositions for inhibiting IKK?/?, including treating disorders associated with IKK?/? activity, including cancer, autoimmune and inflammatory disorders, with a compound of structure:Type: ApplicationFiled: October 24, 2016Publication date: February 16, 2017Applicant: National Institute of Biological Sciences, BeijingInventors: Xiaoguang Lei, Sudan He, Chao Li, Ting Dong
-
Patent number: 9006439Abstract: Disclosed are novel camptothecin derivatives having anti-tumor activity (the basic structure thereof is as shown in the figure) and compositions of such compounds and use thereof. The compounds according to the present invention exhibit very good water solubility and stability, show good selectivity among drugs of the same category, and have a very high therapeutic index. Such compounds are promising as therapeutic agents for treating tumors.Type: GrantFiled: April 6, 2012Date of Patent: April 14, 2015Assignee: Ningbo Team Pharmaceutical Co., LtdInventors: Xiaoguang Lei, Xiuguo Zhang
-
Patent number: 8859615Abstract: The present invention provides compounds of Formula (I), compositions comprising an effective amount of a compound of Formula (I), optionally with chemotherapeutic drugs such as a tubulin-binding drug, and methods of their use for reducing the toxicity of cytotoxic agents, treating or preventing cancer or a neuropathic disorder, inducing a chemoprotective phase II enzyme, DNA, or protein synthesis, enhancing the immune system, treating inflammation, improving and enhancing general health or well-being, and methods for making compounds of Formula (I).Type: GrantFiled: August 27, 2009Date of Patent: October 14, 2014Inventors: Samuel J. Danishefsky, Ting-Chao Chou, Xiaoguang Lei, Heedong Yun, Fay Ng, John Hartung, Dalibor Sames
-
Publication number: 20140011833Abstract: Disclosed are novel camptothecin derivatives having anti-tumor activity (the basic structure thereof is as shown in the figure) and compositions of such compounds and use thereof. The compounds according to the present invention exhibit very good water solubility and stability, show good selectivity among drugs of the same category, and have a very high therapeutic index. Such compounds are promising as therapeutic agents for treating tumors.Type: ApplicationFiled: April 6, 2012Publication date: January 9, 2014Applicant: Ningbo Team Pharmaceutical Co., LtdInventors: Xiaoguang Lei, Xiuguo Zhang
-
Publication number: 20130254139Abstract: Systems and methods disclosed herein relates to building an intelligent assistant that can take in human requests/commands in simple text form, especially in natural language format, and perform tasks for users. Systems and methods are disclosed herein in which knowledge of how to interpret users' requests and carry out tasks, including how to find and manipulate information on the Internet, can be learned from users by the designed assistant, and the knowledge can be subsequently used by the assistant to perform tasks for users.Type: ApplicationFiled: March 18, 2013Publication date: September 26, 2013Inventor: Xiaoguang Lei
-
Publication number: 20110312904Abstract: The present invention provides compounds of Formula (I), compositions comprising an effective amount of a compound of Formula (I), optionally with chemotherapeutic drugs such as a tubulin-binding drug, and methods of their use for reducing the toxicity of cytotoxic agents, treating or preventing cancer or a neuropathic disorder, inducing a chemoprotective phase II enzyme, DNA, or protein synthesis, enhancing the immune system, treating inflammation, improving and enhancing general health or well-being, and methods for making compounds of Formula (I).Type: ApplicationFiled: August 27, 2009Publication date: December 22, 2011Applicants: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Samuel J. Danishefsky, Ting-Chao Chou, Xiaoguang Lei, Heedong Yun, Fay Ng, John Hartung, Dalibor Sames
-
Publication number: 20110124690Abstract: The present invention relates to compositions comprising an effective amount of a Panaxytriol Compound and a tubulin-binding drug, methods for treating or preventing cancer or a neurotrophic disorder comprising administering to a subject in need thereof an effective amount of a Panaxytriol Compound and a tubulin-binding drug, and methods for making a Panaxytriol Compound.Type: ApplicationFiled: February 22, 2008Publication date: May 26, 2011Inventors: Samuel J. Danishefsky, Heedong Yun, Ting-Chao Chou, Xiaoguang Lei, Dalibor Sames
-
Publication number: 20100234348Abstract: The present invention provides compounds that potentiate the activity of antibiotic agents, particularly quinolones such as norflaxin. The invention further provides compositions, e.g., pharmaceutical compositions, comprising the inventive compounds. The invention also provides compositions comprising an antibiotic (e.g., a quinolone) and a compound that potentiates activity of the antibiotic. The invention further provides methods of treating a subject comprising administering any of the inventive compounds or compositions to the subject. The invention also provides screening methods to identify compounds that potentiate the activity of an antibiotic, e.g., a quinolone.Type: ApplicationFiled: August 2, 2007Publication date: September 16, 2010Applicant: TRUSTEES OF BOSTON UNIVERSITYInventors: Guillaume Cottarel, Timothy S. Gardner, Xiaoguang Lei, John Porco, Scott E. Schaus, Jamey Wierzbowski, Kollol Pal